Silver Book Fact

An increase in bone mineral density (BMD) testing and osteoporosis treatment was associated with a decrease in hip fracture incidence.

Jaglal, Susan B., Ian Weller, Muhammad Mamdani, Gillian Hawker, Hans Kreder, Liisa Jaakkimainen, and Jonathan Adachi. Population Trends in BMD Testing, Treatment, and Hip and Wrist Fracture Rates: Are the hip fracture projections wrong?. Arch Intern Med. 2005; 159(11): 1215-20. http://www.ncbi.nlm.nih.gov/pubmed/15883628

Reference

Title
Population Trends in BMD Testing, Treatment, and Hip and Wrist Fracture Rates: Are the hip fracture projections wrong?
Publication
Arch Intern Med
Publication Date
2005
Authors
Jaglal, Susan B., Ian Weller, Muhammad Mamdani, Gillian Hawker, Hans Kreder, Liisa Jaakkimainen, and Jonathan Adachi
Volume & Issue
Volume 159, Issue 11
Pages
1215-20
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Risedronate, a bisphosphonate, has been shown to reduce vertebral fractures by around 41%, hip fractures by 30%, and non-vertebral fractures by 39%.  
  • A recent study found that more postmenopausal women who took the drug denosumab gained at least 3% of bone mass at the hip and spine than those who took…  
  • Alendronate, a bisphosphonate, has been shown to reduce risk of hip fracture by around 53%, clinical vertebral fracture by 45%, and wrist fracture by 30%.  
  • Genetics can account for up to 75% of bone mineral density (BMD). Researchers have identified a gene that strongly influences peak bone mass in mice. The gene was not previously…  
  • A study that looked at a combination of calcium and Vitamin D found that hip fractures were reduced by around 43%.